Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET) from US Patent US11912714: "Spiropyrrolidine derived antiviral agents"
Assay data:47 Active, 48 Activity ≤ 1 µM, 48 Tested
SummaryRelated BioAssays by Target
Measuring Antiviral Effect of Compounds from US Patent US11905306: "Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus"
Assay data:70 Active, 38 Activity ≤ 1 µM, 80 Tested
Antiviral Assay from US Patent US20240043417: "COMPOUNDS FOR THE TREATMENT OF SARS"
Assay data:1 Active, 19 Tested
SARS-CoV-2 3CLpro Enzyme Assay from US Patent US20240043417: "COMPOUNDS FOR THE TREATMENT OF SARS"
Assay data:11 Active, 23 Tested
Antiviral Assay from US Patent US20240034730: "PYRAZOLO DERIVATIVES AS HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS FOR USE AS ANTIVIRALS"
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
SARS-CoV-2 Plaque Assay 2 from US Patent US20240033256: "INHIBITORS OF POSITIVE STRAND RNA VIRUSES"
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SARS-CoV-2 Plaque Assay 1 from US Patent US20240033256: "INHIBITORS OF POSITIVE STRAND RNA VIRUSES"
SARS-CoV-2 Immunofluorescence Assay 2 from US Patent US20240033256: "INHIBITORS OF POSITIVE STRAND RNA VIRUSES"
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
SARS-CoV-2 Immunofluorescence Assay 1 from US Patent US20240033256: "INHIBITORS OF POSITIVE STRAND RNA VIRUSES"
Inhibition of SARS-CoV-2 3CL-Pro proteolytic cleavage of a dual-labeled substrate by FRET at 1mM DTT.
Assay data:24 Active, 19 Activity ≤ 1 µM, 64 Tested
Inhibition of SARS-CoV-2 3CL-Pro proteolytic cleavage of a dual-labeled substrate by FRET.
Assay data:33 Active, 20 Activity ≤ 1 µM, 64 Tested
Inhibition of recombinant SARS-CoV-2 main protease using Dabcyl-KTSAVLQSGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET analysis
Assay data:1 Active, 1 Tested
Inhibition of recombinant SARS-CoV-2 main protease expressed in Escherichia coli BL21 using Dabcyl-EDANS and Boc-Abu-Tle-Leu-Gln-AMC as substrate
Inhibition of SARS-CoV-2 RdRP using ATP substrate preincubated with compound for 30 mins followed by substrate addition and measured after 30 mins by Alphascreen microplate reader analysis
Assay data:2 Active, 2 Tested
Inhibition of MBP tagged recombinant SARS-CoV-2 main protease using DABCYL-KTSAVLeu(13C6,15N)-Q as substrate incubated for 2 to 3 hrs by mass spectrometric analysis
Assay data:2 Active, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of full length SARS-CoV-2 3CL protease expressed in Escherichia coli BL21 (DE3) using Dacyl-KTSAVLQSGFRKME-Edans fluorogenic peptide as substrate pre-incubated for 10 mins followed by substrate addition by FRET assay
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
Inhibition of full length SARS-CoV-2 3CL protease expressed in Escherichia coli BL21 (DE3) at 10 uM using Dacyl-KTSAVLQSGFRKME-Edans fluorogenic peptide as substrate pre-incubated for 10 mins followed by substrate addition by FRET assay relative to control
Assay data:11 Tested
Inhibition of full length SARS-CoV-2 3CL protease expressed in Escherichia coli BL21 (DE3) at 1 uM using Dacyl-KTSAVLQSGFRKME-Edans fluorogenic peptide as substrate pre-incubated for 10 mins followed by substrate addition by FRET assay relative to control
Assay data:8 Tested
Inhibition of full length SARS-CoV-2 3CL protease expressed in Escherichia coli BL21 (DE3) at 0.1 uM using Dacyl-KTSAVLQSGFRKME-Edans fluorogenic peptide as substrate pre-incubated for 10 mins followed by substrate addition by FRET assay relative to control
Assay data:7 Tested
Inhibition of full length SARS-CoV-2 3CL protease expressed in Escherichia coli BL21 (DE3) at 0.02 uM using Dacyl-KTSAVLQSGFRKME-Edans fluorogenic peptide as substrate pre-incubated for 10 mins followed by substrate addition by FRET assay relative to control
Assay data:4 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on